ArticlePloS one2012
A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Utilizing induced neural stem cell-based delivery of a cytokine cocktail to enhance chimeric antigen receptor-modified T-cell therapy for brain cancer.Bioengineering & translational medicine · 2023Article
- Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence.Molecular therapy oncolytics · 2022Article
- Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers.Drug delivery and translational research · 2021Article
- Stem cells for the treatment of glioblastoma: a 20-year perspective.CNS oncology · 2021Review
- Neural Stem Cell-Based Therapies and Glioblastoma Management: Current Evidence and Clinical Challenges.International journal of molecular sciences · 2021Review
- Article
- Generation and Profiling of Tumor-Homing Induced Neural Stem Cells from the Skin of Cancer Patients.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.PloS one · 2018Article
- Enhanced tumor growth inhibition by mesenchymal stem cells derived from iPSCs with targeted integration of interleukin24 into rDNA loci.Oncotarget · 2017Article
- Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.Science translational medicine · 2017Article
- Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma.Biomaterials · 2016Article
- Neural stem cell therapy for cancer.Methods (San Diego, Calif.) · 2016Review
- Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer.Biomaterials · 2016Article
- Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.Nature communications · 2016Article
- Gene Therapies for Cancer: Strategies, Challenges and Successes.Journal of cellular physiology · 2015Review
- Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24.International journal of cancer · 2013Article
- A high-throughput cell-based Gaussia luciferase reporter assay for identifying modulators of fibulin-3 secretion.Journal of biomolecular screening · 2013Article
- Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules.Anti-cancer agents in medicinal chemistry · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Creating new molecules that simultaneously enhance tumor cell killing and permit diagnostic tracking is vital to overcoming the limitations rendering current therapeutic regimens for terminal cancers ineffective. Accordingly, we investigated the efficacy of an innovative new multi-functional targeted anti-cancer molecule, SM7L, using models of the lethal brain tumor Glioblastoma multiforme (GBM). Designed using predictive computer modeling, SM7L incorporates the therapeutic activity of the promising anti-tumor cytokine MDA-7/IL-24, an enhanced secretory domain, and diagnostic domain for non-invasive tracking. In vitro assays revealed the diagnostic domain of SM7L produced robust photon emission, while the therapeutic domain showed marked anti-tumor efficacy and significant modulation of p38MAPK and ERK pathways. In vivo, the unique multi-functional nature of SM7L allowed simultaneous real-time monitoring of both SM7L delivery and anti-tumor efficacy. Utilizing engineered stem cells as novel delivery vehicles for SM7L therapy (SC-SM7L), we demonstrate that SC-SM7L significantly improved pharmacokinetics and attenuated progression of established peripheral and intracranial human GBM xenografts. Furthermore, SC-SM7L anti-tumor efficacy was augmented in vitro and in vivo by concurrent activation of caspase-mediated apoptosis induced by adjuvant SC-mediated S-TRAIL delivery. Collectively, these studies define a promising new approach to treating highly aggressive cancers, including GBM, using the optimized therapeutic molecule SM7L.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.